Does CLA Help With Weight Loss? What the Trials and FDA Records Show

CLA supplements do not produce weight loss anyone would notice. Pooled across 70 randomized trials and 4,159 people, conjugated linoleic acid took off 0.35 kg more than placebo, less than a pound, and when the analysis was limited to the better-run trials, the fat-loss effect disappeared.^[3] The most generous estimate, from 2007, was about 0.09 kg of fat a week at 3.2 g a day, a rate that flattens after six months.^[1] Against that sit safety signals that are small but not trivial: in obese men, one of the two main CLA isomers made insulin resistance worse in a 12-week trial,^[10] and long-term trials recorded rises in lipoprotein(a).^[7] The FDA’s “no questions” letter on CLA as a food ingredient is not an endorsement of any weight-loss claim.^[23]

What CLA is

Conjugated linoleic acid is not one substance. It is a family of fatty acids that differ from ordinary linoleic acid in where their double bonds sit. Small amounts occur naturally in beef, milk and cheese, almost all of it as one form, cis‑9,trans‑11.^[23] Supplements are made differently: safflower oil is chemically converted into a roughly 50:50 mix of that form and a second one, trans‑10,cis‑12.^[23] The distinction matters, because the two forms do not behave the same way in the body, and most of the safety concerns attach to the second.

The weight-loss idea came from animals, where CLA reliably reduces fat. In people the trial results were inconsistent from the start, which is why researchers turned to pooling them.^[1]

The meta-analyses, side by side

The first pooled analysis, from the University of Wisconsin, used 18 placebo-controlled trials that measured body fat with a validated method. It found fat loss of 0.024 kg per gram of CLA per week, which works out to about 0.09 kg a week against placebo at the median dose of 3.2 g a day.^[1] The effect ran in a straight line for about six months and then leveled off. At that rate, six months comes to a little over 2 kg of fat, and the authors called the result “modest.”^[1]

Later analyses asked harder questions and got smaller answers. A team at the University of Exeter kept only trials that lasted at least six months. Of 15 candidates, 7 qualified, and 4 of those had serious flaws in how their methods were reported. CLA beat placebo by 0.70 kg of weight and 1.33 kg of fat, and the authors concluded the evidence “does not convincingly show” any clinically relevant long-term effect.^[2] A 2019 pooling of 13 trials in people with overweight or obesity found 0.52 kg, with no change in waist size.^[4]

The largest analysis, published in 2024, pooled 70 trials. Weight fell 0.35 kg more than on placebo, fat 0.44 kg, and lean mass rose 0.27 kg. The detail that matters most is in the quality split: in the high-quality trials, CLA “fails to change” fat mass or body fat percentage.^[3] When a supplement’s effect shrinks as the trials get better, the likeliest explanation is that the weaker trials overstated it.

For scale, semaglutide 2.4 mg in its main obesity trial produced 12.7 kg more weight loss than placebo over 68 weeks.^[6] The best CLA estimate is about one-eighteenth of that. CLA also has no GLP‑1 link: no human study has shown that CLA raises GLP‑1, and none has tested it alongside a GLP‑1 drug. Our review of supplements sold as GLP-1 boosters covers the products that do make that claim.

What the long trials show

The longest CLA trial is the strongest argument for it and the clearest picture of its limits. In Norway, 180 adults with overweight took CLA in one of two forms or olive oil for a year. Body fat ended 7% to 9% lower in the CLA groups than on placebo.^[7] In an open second year, everyone took CLA. The former placebo group then lost 1.7 kg of fat, but the people already on CLA lost nothing more.^[8] The effect came in the first year and did not build after that.

It also does not appear to protect weight that has already come off. In a Dutch trial, 54 adults lost weight on a very-low-calorie diet and then took CLA or placebo for 13 weeks. CLA restored slightly more lean tissue but “did not result in improved body weight maintenance.”^[9] For people on a GLP‑1 who are worried about regain, that is the question that counts, and CLA has not answered it.

Exercise does not rescue the result either. A 2023 analysis of 20 trials comparing CLA plus exercise with exercise alone found slightly more fat lost with CLA, but concluded that the combination “does not reduce body weight.”^[26]

The safety signals

Most trials report CLA as well tolerated, with stomach upset, loose stools and constipation the usual complaints.^[2] The concerns are metabolic, and they came from careful trials in exactly the people most likely to buy a fat-loss supplement.

Insulin resistance in obese men

At Uppsala University, 60 men with abdominal obesity took 3.4 g a day of either the trans‑10,cis‑12 form, the standard mixture, or placebo for 12 weeks. Insulin resistance was measured with a glucose clamp, the most exact method available. The trans‑10,cis‑12 form increased insulin resistance by 19% and blood sugar by 4%, and lowered HDL cholesterol by 4%, against placebo. It did not reduce body fat more than placebo did.^[10] The same men showed a 578% rise in a urine marker of oxidative stress and a 110% rise in C-reactive protein, a marker of inflammation.^[11] A follow-up analysis found the isomer raised proinsulin, a marker linked to future diabetes, and its authors wrote that weight-loss supplements containing it were “worrying.”^[12]

The form found in food carries its own signal. In a separate trial of 25 obese men, the cis‑9,trans‑11 form cut insulin sensitivity by 15% over three months, again with no change in body composition.^[13]

The 50:50 mixture that most products contain looks milder. It did not change glucose metabolism in the Uppsala trial,^[10] and a six-month clamp study of 41 people found no effect on insulin sensitivity.^[14] But a 2023 pooling of 13 trials in people at risk of heart disease found CLA raised fasting blood sugar by about 4.5 mg/dL, while HbA1c and a standard insulin-resistance score did not move.^[15] So the pure isomers can worsen insulin action in men with abdominal obesity, and the mixture has not clearly done so. The men in whom the signal appeared belong to the population most often prescribed GLP‑1 drugs.

Cholesterol and lipoprotein(a)

The lipid results point in different directions. In the year-long Norwegian trial, lipoprotein(a), a cholesterol-carrying particle linked to heart disease, rose in both CLA groups from the start of the study; LDL cholesterol rose in one group and HDL fell in the other.^[7] Lipoprotein(a) rose again in the open second year.^[8] One meta-analysis found CLA supplements lowered LDL slightly,^[21] and another found no adverse effect on lipids or blood pressure in people at heart risk.^[5] A 12-week Welsh trial of the mixture found worse blood-vessel function, measured as a 1.3 percentage-point drop in flow-mediated dilation, and its authors concluded CLA “cannot be recommended” for weight loss.^[16]

The liver

CLA enlarges the liver in animals.^[27] In people, the evidence is reassuring on average, with two serious exceptions. Pooled trials found a small rise in AST, one of the standard liver enzymes, with no change in ALT;^[17] a larger 2022 pooling of 22 trials found neither enzyme changed.^[18] Twenty healthy adults given 19.3 g a day, about six times the usual dose, for three weeks had no clinically relevant change in liver or kidney tests.^[27] The one trial that scanned the liver directly found no change in liver fat.^[16]

The exceptions are two case reports. A 46-year-old woman developed toxic hepatitis 14 days after starting CLA to lose fat, confirmed by liver biopsy, and recovered after stopping.^[19] A 63-year-old woman developed fulminant liver failure that required a transplant, attributed after investigation to a CLA weight-loss supplement.^[20] Case reports cannot give a rate, and supplements can contain more than their labels say. They are reasons to stop at once if jaundice, dark urine or itching appears. For what liver enzyme results mean on a GLP‑1 drug, see GLP-1 drugs and liver enzymes.

What GRAS status does and does not mean

CLA makers often cite GRAS status, which stands for “generally recognized as safe.” The record is narrower than that sounds. A first notice from the ingredient maker Cognis was withdrawn in 2004 before FDA finished evaluating it. A resubmission, GRN 232, closed in July 2008 with FDA’s standard reply that it had “no questions.”^[22] That notice covered a 50:50 isomer mixture added to soy milk, meal-replacement drinks and bars, milk products and fruit juices at no more than 1.5 g a serving.^[23] A 2009 follow-up raised the ceiling to 3 g per person per day, and FDA added that it “has not, however, made its own determination” on GRAS status.^[24] A second company’s notice, GRN 521, closed the same way in 2014.^[22]

The Office of Food Additive Safety (OFAS) neither consulted with ONLDS on this labeling issue nor evaluated the information in your notice to determine whether it would support any claims made about CLA-isomers on the label or in labeling.

— FDA response letter, GRAS Notice 232, 2008

Three limits follow. GRAS is a food-ingredient finding for set foods at set amounts, not a finding that CLA causes weight loss. FDA’s letter explicitly did not look at whether any claim on a label was supported.^[23] And capsules sold as dietary supplements do not need GRAS status at all: under the 1994 supplement law, FDA “is not authorized to approve dietary supplements for safety and effectiveness before they are marketed.”^[25] The 3 g a day in the 2009 letter is roughly the dose used in most weight trials, so it is not a margin above them.

Where CLA fits

CLA is one of the better-studied weight supplements, which is why its answer is so clear. Seventy trials converge on a fraction of a kilogram. It sits with capsaicin and capsinoids, whose pooled trials found nothing on the scale, ahead of raspberry ketones, which have never been tested alone in people, and with the products reviewed in do GLP-1 supplements work. Our supplement evidence grader lists CLA alongside 15 other supplements with the primary study behind each. The small lean-mass gain seen in some CLA trials, about a quarter of a kilogram, is also far below what resistance training and protein do; see lean mass on a drug versus dieting.

For anyone already on a GLP‑1 drug, there is no trial of the combination and no reason to expect CLA to add a meaningful amount. For anyone with prediabetes, type 2 diabetes or abdominal obesity, the insulin-resistance trials are a specific reason not to take it.